Candel Therapeutics CADL Institutional Ownership

Updated Oct 11, 2026

Candel Therapeutics, Inc. (NASDAQ:CADL) had 138 institutional holders reporting a position on Form 13F for the quarter ended June 30, 2026.

• These investors held 66.49% of Candel Therapeutics' outstanding shares at the end of Q2 2026, up from 59.18% in Q1 2026.
• Total holdings of CADL shares rose 16.53% from Q1 2026, and the holder count rose 81.58% from Q2 2025.
• Looking at the 138 holders of CADL individually, 104 added to their positions, 23 reduced their stakes and 11 left their positions unchanged.
• Altogether, institutional holders owned 50.61Mn CADL shares at the end of Q2 2026, up 7.18Mn from the prior quarter and up 27.69Mn from a year earlier.
• FMR LLC was the top holder of Candel Therapeutics as of June 30, 2026, with 10.99Mn shares, or 14.44% of shares outstanding.
• The biggest increases in CADL positions during Q2 2026 came from State Street Corp (+2.73Mn shares), BlackRock, Inc. (+1.86Mn shares), Portolan Capital Management, LLC (+596.07K shares), Geode Capital Management, LLC (+535.59K shares) and Saturn V Capital Management LP (+407.1K shares).
• The biggest cuts to CADL positions during Q2 2026 came from Halter Ferguson Financial Inc. (-131.59K shares), Kynam Capital Management, LP (-103.26K shares), Ghisallo Capital Management LLC (-100K shares), Two Sigma Investments, LP (-60.77K shares) and Hudson Bay Capital Management LP (-34.21K shares).
• Per Business Quant, the top 10 investors in CADL for the quarter ended June 30, 2026 were FMR LLC (10.99Mn shares), RTW Investments, LP (6.42Mn shares), BlackRock, Inc. (4.97Mn shares), State Street Corp (3.55Mn shares), Acorn Capital Advisors, LLC (3.5Mn shares), Portolan Capital Management, LLC (3.49Mn shares), Saturn V Capital Management LP (3.3Mn shares), Vanguard Capital Management LLC (2.69Mn shares), Geode Capital Management, LLC (1.57Mn shares) and Millennium Management LLC (1.09Mn shares).